Clover Biopharmaceuticals Announces Positive Phase 1 Data for its Adjuvanted S-Trimer COVID-19 Vaccine Candidates

Clover’s protein-based COVID-19 vaccine candidates adjuvanted with either GSK’s pandemic adjuvant system or Dynavax’s CpG 1018 plus alum induced strong neutralizing immune responses in 150 adult and elderly subjects from the Phase 1 clinical study.  Clover’s vaccine candidates both demonstrated a favorable safety and tolerability profile, and have also shown long-term stability at 2-8oC, making them …

Clover Biopharmaceuticals Announces Positive Phase 1 Data for its Adjuvanted S-Trimer COVID-19 Vaccine Candidates Read More »

CEPI extends partnership with Clover Biopharmaceuticals to fund COVID-19 vaccine candidate through global Phase 2/3 study to licensure

CEPI to fund the development of Clover’s protein-based S-Trimer vaccine candidate through to licensure, including a global pivotal Phase 2/3 efficacy clinical study beginning before the end of 2020. Agreement between CEPI and Clover anticipates that the vaccine – if proven to be safe and effective – will be made available for procurement and allocation …

CEPI extends partnership with Clover Biopharmaceuticals to fund COVID-19 vaccine candidate through global Phase 2/3 study to licensure Read More »

Clover Announces Formation of a Global Scientific Advisory Board for its COVID-19 Vaccine Program

SAB to provide strategic guidance for the global development of Clover’s COVID-19 vaccine program Comprised of prominent vaccine and industry experts from around the world CHENGDU, CHINA, September 25, 2020 – Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on discovering and developing transformative biologic therapies and vaccines, today announced the formation of its Scientific …

Clover Announces Formation of a Global Scientific Advisory Board for its COVID-19 Vaccine Program Read More »

Clover Announces Positive Preclinical Data and Updates on Phase 1 Study for its Adjuvanted S-Trimer COVID-19 Vaccine Candidate

Preclinical data show Clover’s protein-based adjuvanted COVID-19 vaccine candidate, S-Trimer, induces a strong neutralizing immune response in animals and protects nonhuman primates from SARS-CoV-2 challenge  Strong immune response and protection observed with adjuvant systems from GSK and Dynavax led to inclusion of both adjuvants separately into Clover’s ongoing Phase 1 clinical trial of S-Trimer  Clover’s …

Clover Announces Positive Preclinical Data and Updates on Phase 1 Study for its Adjuvanted S-Trimer COVID-19 Vaccine Candidate Read More »

CEPI expands partnership with Clover to rapidly advance development and manufacture of COVID-19 vaccine candidate

CEPI to invest an additional $66m upfront in Clover’s S-Trimer protein vaccine candidate. Funding will support clinical development in parallel with scale-up of manufacturing capacity to potentially produce hundreds of millions of doses per year. OSLO, NORWAY, July 8, 2020—CEPI, the Coalition for Epidemic Preparedness Innovations, today announced the expansion of its partnership with Sichuan …

CEPI expands partnership with Clover to rapidly advance development and manufacture of COVID-19 vaccine candidate Read More »

Clover Initiates Phase 1 Clinical Trial for COVID-19 Vaccine Candidate

150 healthy adult and elderly participants expected to be enrolled in Phase 1 study COVID-19 vaccine candidate to be evaluated in combination with GSK’s pandemic adjuvant system and Dynavax’s CpG 1018 adjuvant following promising preclinical study results Preliminary safety and immunogenicity results expected in August 2020 Global Phase 2b/3 vaccine efficacy study is in planning …

Clover Initiates Phase 1 Clinical Trial for COVID-19 Vaccine Candidate Read More »

GL Ventures Completes $24 Million Series B-2 Investment in Clover Biopharmaceuticals

BEIJING, CHINA, June 8, 2020 – Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, today announced the completion of a US$ 24 million Series B-2 financing from GL Ventures. This financing round brings Clover’s total capital raised since 2016 to over US$ 140 million. “We are pleased to …

GL Ventures Completes $24 Million Series B-2 Investment in Clover Biopharmaceuticals Read More »

CEPI announces COVID-19 vaccine development partnership with Clover Biopharmaceuticals’ Australian Subsidiary

CEPI to provide initial US$3.5m to Clover Biopharmaceuticals Australia, the wholly-owned subsidiary of Sichuan Clover Biopharmaceuticals, Inc (China) to support preparation and initiation of a phase 1 trial of Clover’s protein-based COVID-19 S-Trimer vaccine in Australia Partnership becomes ninth global COVID-19 vaccine development project that CEPI has signed since Jan 23, 2020 OSLO, NORWAY, April …

CEPI announces COVID-19 vaccine development partnership with Clover Biopharmaceuticals’ Australian Subsidiary Read More »

Dynavax and Clover Biopharmaceuticals Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with CpG 1018 Adjuvant

Dynavax is providing CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, to support the rapid development of Clover’s COVID-19 vaccine Clover advancing evaluation of its protein-based coronavirus vaccine candidate (COVID-19 S-Trimer) EMERYVILLE, CA AND CHENGDU, CHINA, March 24, 2020 – Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing …

Dynavax and Clover Biopharmaceuticals Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with CpG 1018 Adjuvant Read More »

Clover and GSK Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with Pandemic Adjuvant System

CHENGDU, CHINA AND LONDON UK, February 24, 2020 – Clover Biopharmaceuticals, a China based global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, announced today that it has entered into a research collaboration with GSK for its protein-based coronavirus vaccine candidate (COVID-19 S-Trimer). GSK will provide Clover with its pandemic adjuvant system …

Clover and GSK Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with Pandemic Adjuvant System Read More »